Relative Effectiveness of Faricimab Vs Aflibercept 8 Mg after Loading Phase in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema

Speaker(s)

Bührer C1, Tabano D2, Cox O1, Macia G1
1F. Hoffmann-La Roche, Basel, BS, Switzerland, 2Genentech, Inc., South San Francisco, CA, USA

Presentation Documents

OBJECTIVES: Faricimab is a bispecific antibody targeting ANG-2 and VEGF for the treatment of nAMD and DME. Faricimab was investigated in four studies vs. aflibercept 2mg. Recently; aflibercept was investigated at a higher dosage (8mg). This research aims at investigating the relative effectiveness of faricimab vs. aflibercept 8mg. We specifically look at the outcomes after the loading phase when both treatments were given monthly to exclude the effect of dosing related differences as both treatments were given in flexible regimens thereafter.

METHODS: A targeted literature review was conducted to identify randomized clinical trials using aflibercept 8mg in nAMD and DME. The main outcome was change in best corrected visual acuity (BCVA) and central subfield thickness (CST) from baseline until the end of the loading phase (12 weeks). Seven studies with relevant data were eligible informing a Bayesian Network Meta-Analysis (NMA) to estimate the efficacy of faricimab vs. aflibercept 8mg. Differences and the probability of faricimab being better were calculated using fixed-effect (FE) models (base case) and random-effects (RE) models (sensitivity analysis).

RESULTS: At the 12-week time point, the mean change in BCVA was numerically greater with faricimab in DME (95% Crl: -2.6, 0.68) and statistically greater in nAMD (-3.2, -0.49). The associated probability of faricimab showing better vision outcomes in both indications was about 90% or higher. The mean change in CST was statistically greater with faricimab in DME (2.8, 40) and numerically greater in nAMD (-3.2, 33). The associated probability of faricimab showing better retinal drying outcomes was greater than 90% in both indications. RE results were generally consistent.

CONCLUSIONS: Results from the NMA demonstrate that after the loading phase there is a high probability that faricimab is associated with a greater effect on retinal drying than aflibercept 8mg in both indications achieving similar or better vision outcomes.

Code

CO187

Topic

Clinical Outcomes, Study Approaches

Topic Subcategory

Comparative Effectiveness or Efficacy, Literature Review & Synthesis, Meta-Analysis & Indirect Comparisons

Disease

Sensory System Disorders (Ear, Eye, Dental, Skin)